Form 4: Cytek Biosciences COO Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Paul Christopher Williams, COO of Cytek Biosciences, was granted stock options and restricted stock units (RSUs) on March 6, 2024, according to a Form 4 filing with the SEC.
Summary
- Paul Christopher Williams, the Chief Operating Officer of Cytek Biosciences, Inc., received stock options and restricted stock units (RSUs) on March 6, 2024.
- The stock options grant is for 210,526 shares with an exercise price of $7.07 per share.
- These options vest over four years, starting April 6, 2024, with 1/48th of the shares vesting monthly.
- Williams also received 141,442 RSUs, each representing a contingent right to receive one share of Cytek's common stock.
- The RSUs also vest over four years, with vesting dates occurring on May 18, August 18, November 18, and March 10 of each year, starting in 2024 and 2025 respectively.
- Following these transactions, Williams directly owns 210,526 shares via stock options and 141,442 shares via restricted stock units.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice and indicates confidence in the executive and the company's future performance. There are no immediate negative implications.
Positives
- The grant of stock options and RSUs to the COO aligns his interests with those of the shareholders.
- The vesting schedules encourage long-term commitment from the COO.
Industry Context
Stock option and RSU grants are common compensation practices for executives in publicly traded companies, particularly in the biotech and technology sectors, to incentivize performance and retain key personnel.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- Companies like Illumina, Thermo Fisher Scientific, and Danaher also utilize stock options and RSUs to incentivize their executives.
- The vesting schedules described are typical for such grants, aligning with industry norms for retention and performance incentives.
Stakeholder Impact
- Shareholders may view the grants positively as they align management's interests with the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/06/2024 | Date of the transaction (grant of stock options and RSUs) |
| 03/06/2034 | Expiration date of the stock options |
| 04/06/2024 | First vesting date for the stock options (1/48th of total shares) |
| 05/18/2024 | First vesting date for the RSUs (2/48th of total shares) |
| 08/18/2024 | Second vesting date for the RSUs (3/48th of total shares) |
| 11/18/2024 | Third vesting date for the RSUs (3/48th of total shares) |
| 03/10/2025 | Fourth vesting date for the RSUs (4/48th of total shares) |
| 03/08/2024 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.